Masimo will operate as a stand-alone business within the Danaher diagnostics segment, focusing on patient monitoring and pulse oximetry.
Danaher Corp has completed its acquisition of Masimo Corp, a developer of pulse oximetry and patient monitoring solutions used primarily in acute care settings.
Following the close of the transaction, Masimo is now a wholly owned subsidiary of Danaher. It will continue to operate under its existing brand as a stand-alone company within the Danaher diagnostics segment. As a result of the deal, Masimo common stock has ceased trading on the Nasdaq Stock Market.
The acquisition integrates Masimo’s brand, advanced sensor technology, and AI-enabled patient monitoring into the Danaher diagnostics portfolio.
“Masimo is a strong strategic fit for Danaher. Together, we expect to strengthen our ability to deliver differentiated products in acute care settings and accelerate Masimo’s growth and global reach,” says Julie Sawyer Montgomery, executive vice president of diagnostics at Danaher, in a release.
The consideration for former Masimo stockholders will be paid according to the merger agreement terms described in filings with the US Securities and Exchange Commission.
Regarding its financial outlook, Danaher has not changed its previously communicated guidance for the second quarter or full year of 2026, excluding the expected contribution from Masimo. The company stated it does not anticipate a material contribution from Masimo during the second quarter of 2026. Danaher intends to update its full-year 2026 guidance to incorporate Masimo’s expected contribution during its second-quarter earnings release.
ID 402695003 © Patrickmcdonnell | Dreamstime.com
